Business
Sareum to Present at BioTrinity 2017
Sareum to Present at BioTrinity 2017.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4772E Sareum Holdings PLC 09 May 2017 \n\n9 May 2017\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\nSareum to Present at BioTrinity 2017\nDr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will be giving two presentations at BioTrinity 2017 currently being held at the Novotel London West, Hammersmith International Centre, London until 10th May. \nDr Mitchell will be showcasing the Company and its lead programmes in the \"Early Stage Therapeutics 1\" session today at 13.50pm and has been invited by the organisers to present to a panel of investors tomorrow (10th May) at the \"Perfect Pitch\" session being held at 15:00. \nBioTrinity is one of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK. The event is attended by global life science investors, big pharma executives and emerging R&D companies. \nDr Tim Mitchell, CEO of Sareum, commented: \"BioTrinity offers us ideal opportunities to present our latest developments to both investors and potential licence partners.\"\nJohn Harris, CEO of OBN, said: \"We are delighted that Sareum will be presenting at BioTrinity this year. BioTrinity is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2017.\"\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nThe Communications Portfolio (Sareum Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\nNotes for editors: \nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum operates an outsourced research model, working with internatio...